SBIR Phase I: Integrated CMOS Microarray Disposable for Handheld Oligonulceotide Diagnostics

这项小型企业创新研究(SBIR)第一阶段的研究将导致一种新型的一次性微阵列设备，该设备将固体表面寡核苷酸合成与CMOS成像传感器相结合。由于该技术涉及荧光团/发射体和探测器之间的直接耦合，而不是成像光学系统，因此该方法提供了一种比目前的微阵列仪器具有更高的灵敏度和更低的成本的小占地仪器的手段。这种方法将取代大型台式检测仪器，对于需要为新兴的遗传诊断领域执行常规或现场微阵列诊断的学术机构和较小的非实验室机构来说，这是一个真正的规模和成本障碍。拟议的几何结构还将包括纳米材料的集成，这将使硅CMOS传感器具有较高的背景抑制能力。随着紧凑型阅读器仪器和新的信号转导方法的成功实施，将开发一种新的微阵列检测和分析方法，用于在护理点进行疾病概况分析和在事件点进行生物碱检测。这项研究工作的产品将导致开发微阵列一次性仪器和相关的读取器仪器，它们比目前的仪器更便宜，尺寸更小，并且不会牺牲灵敏度或吞吐量。这类微阵列技术作为不断发展的遗传诊断领域的通用平台的发展，将在基因表达谱、药物基因组学和药物发现、基因测序、疾病状态谱和其他遗传诊断(例如寄生虫、病原体)等领域提供增强的能力。

This Small Business Innovation Research (SBIR) Phase I research will lead to a novel disposable microarray device that combines solid-surface oligonucleotide synthesis with a CMOS imaging sensor. Since this technique involves direct coupling between fluorophore/emitter and the detector instead of an imaging optical system, the method provides a means for a small-footprint instrument with higher sensitivity and lower cost than present microarray instrumentation. The method will replace large benchtop detection instrumentation that are a real size and cost barrier for academic and smaller non-laboratory institutions that need to perform routine or fielded microarray diagnostics for the emerging field of genetic diagnostics. The proposed geometry will also include the integration of nanophase material that will enable high background rejection on the silicon CMOS sensor. With successful implementation of the compact reader instrumentation and novel signal transduction method, a new approach for microarray detection and analysis will be developed for applications such as disease profiling at the point-of-care and biothreat detection at the point-of-incident. The product of this research effort will lead to the development of microarray disposables, and associated reader instrumentation, that are less expensive and much smaller in size than present instrumentation and do not sacrifice sensitivity or throughput. Development of this type of microarray technology as a general purpose platform for the evolving field of genetic diagnostics will provide enhanced capabilities in areas such as gene expression profiling, pharmacogenomics and drug discovery, genetic sequencing, disease state profiling and other genetic diagnostics (e.g. parasites, pathogens).